PIK3CA and breast carcinoma: For example, alpelisib, as a drug targeting PI3Kα, combined with fulvestrant are used to treat advanced or metastatic postmenopausal female or male breast cancer (whose tumor is HR positive, HER2 negative, and with the PIK3CA mutation) [22].